Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Becton, Dickinson and Company (BDX) Competitors

$232.04
+5.26 (+2.32%)
(As of 05/31/2024 ET)

BDX vs. ABT, ISRG, SYK, BSX, MDT, EW, DXCM, IDXX, RMD, and STE

Should you be buying Becton, Dickinson and Company stock or one of its competitors? The main competitors of Becton, Dickinson and Company include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Medtronic (MDT), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.

Becton, Dickinson and Company vs.

Abbott Laboratories (NYSE:ABT) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Abbott Laboratories has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Abbott Laboratories has higher revenue and earnings than Becton, Dickinson and Company. Abbott Laboratories is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$40.11B4.41$5.72B$3.2131.64
Becton, Dickinson and Company$19.37B3.42$1.48B$4.5450.53

In the previous week, Abbott Laboratories had 1 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 23 mentions for Abbott Laboratories and 22 mentions for Becton, Dickinson and Company. Abbott Laboratories' average media sentiment score of 0.54 beat Becton, Dickinson and Company's score of 0.48 indicating that Becton, Dickinson and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abbott Laboratories
11 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Becton, Dickinson and Company
9 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.2%. Becton, Dickinson and Company pays an annual dividend of $3.80 per share and has a dividend yield of 1.7%. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 83.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has raised its dividend for 53 consecutive years and Becton, Dickinson and Company has raised its dividend for 52 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.1% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Abbott Laboratories received 331 more outperform votes than Becton, Dickinson and Company when rated by MarketBeat users. Likewise, 69.64% of users gave Abbott Laboratories an outperform vote while only 62.33% of users gave Becton, Dickinson and Company an outperform vote.

CompanyUnderperformOutperform
Abbott LaboratoriesOutperform Votes
920
69.64%
Underperform Votes
401
30.36%
Becton, Dickinson and CompanyOutperform Votes
589
62.33%
Underperform Votes
356
37.67%

Abbott Laboratories has a net margin of 13.96% compared to Abbott Laboratories' net margin of 6.76%. Becton, Dickinson and Company's return on equity of 20.18% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Abbott Laboratories13.96% 20.18% 10.60%
Becton, Dickinson and Company 6.76%13.90%6.73%

Abbott Laboratories currently has a consensus target price of $120.64, suggesting a potential upside of 18.21%. Becton, Dickinson and Company has a consensus target price of $280.17, suggesting a potential upside of 21.67%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Becton, Dickinson and Company is more favorable than Abbott Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abbott Laboratories
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
Becton, Dickinson and Company
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Summary

Abbott Laboratories beats Becton, Dickinson and Company on 15 of the 21 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDX vs. The Competition

MetricBecton, Dickinson and CompanySurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$66.30B$3.86B$5.03B$17.74B
Dividend Yield1.69%1.81%2.82%3.57%
P/E Ratio50.539.83135.9622.93
Price / Sales3.4268.962,369.1210.29
Price / Cash11.1347.9234.2318.88
Price / Book2.585.085.485.87
Net Income$1.48B$4.50M$105.36M$976.92M
7 Day Performance0.26%1.48%0.83%0.28%
1 Month Performance-2.22%1.42%3.21%4.90%
1 Year Performance-5.13%-15.92%4.28%24.34%

Becton, Dickinson and Company Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ABT
Abbott Laboratories
4.9474 of 5 stars
$101.95
-1.9%
$120.60
+18.3%
+0.0%$177.36B$40.11B31.76114,000Analyst Forecast
ISRG
Intuitive Surgical
4.372 of 5 stars
$401.03
-0.9%
$396.17
-1.2%
+31.4%$142.25B$7.12B72.3913,676Analyst Forecast
Insider Selling
Short Interest ↑
SYK
Stryker
4.8729 of 5 stars
$339.34
+1.1%
$370.50
+9.2%
+25.4%$129.27B$20.96B38.7452,000Analyst Forecast
BSX
Boston Scientific
4.5939 of 5 stars
$75.17
-0.6%
$75.41
+0.3%
+48.5%$110.28B$14.71B63.1748,000Analyst Forecast
Insider Selling
Short Interest ↓
MDT
Medtronic
4.8851 of 5 stars
$82.00
-0.4%
$94.00
+14.6%
-2.3%$108.88B$32.36B29.8295,000Analyst Forecast
EW
Edwards Lifesciences
4.8923 of 5 stars
$87.04
-1.1%
$94.31
+8.4%
+7.9%$52.45B$6.00B37.5219,800Analyst Forecast
Insider Selling
Short Interest ↓
DXCM
DexCom
4.9563 of 5 stars
$127.38
+0.0%
$141.67
+11.2%
+4.3%$50.66B$3.62B82.189,600Analyst Forecast
Short Interest ↓
IDXX
IDEXX Laboratories
4.3173 of 5 stars
$505.40
-2.1%
$580.38
+14.8%
+7.2%$41.74B$3.66B48.9311,000Positive News
RMD
ResMed
4.4948 of 5 stars
$207.17
-2.9%
$202.80
-2.1%
-0.3%$30.44B$4.22B31.8210,140Analyst Revision
STE
STERIS
4.0015 of 5 stars
$223.39
-2.5%
$241.60
+8.2%
+11.9%$22.07B$5.14B58.4817,100Analyst Downgrade
Analyst Revision

Related Companies and Tools

This page (NYSE:BDX) was last updated on 5/31/2024 by MarketBeat.com Staff

From Our Partners